) -- The biotech sector in rewind for the week ending Oct. 8, 2010:
launched a $69-a-share hostile tender offer for
( GENZ) after efforts failed to reach a takeover agreement with Genzyme management on more friendly terms. Then, both companies bickered over whether Sanofi offered $80-a-share, or not. Next week, the scheduling of the muay thai bout between Sanofi's Chris Viehbacher and Genzyme's Henri Termeer. My money is on Viehbacher.
The FDA extended the review period for
Xifaxan by three months to March 7, 2011. Salix is seeking to expand Xifaxan's approved label to include the treatment of non-constipation irritable bowel syndrome. The original FDA drug approval decision date was Dec. 7.
CEO Jim Bianco sold 400,000 shares of company stock at 37-38 cents a share.
(Not so) fun fact: $1.7 billion in funds exited the healthcare sector in the first nine months of the year, while $15.2 billion in funds were sunk into all equity funds during the same time period, according to
. (Hat tip: ISI Group biotech analyst Mark Schoenebaum.)
The week's top-performing sector stocks:
( NLTX) (+21%).
raises $1.25 billion through a corporate bond sale; Cyclacel Pharmaceuticals nets $14 million in a private placement of stock and warrants.
Notable financing for all the wrong reasons:
pulls the trigger on an intraday, Rodman and Renshaw-led preferred stock and warrants sale just hours after releasing questionable phase III diabetes data.
with complete response letters issued to
for the pain reliever Dyloject and
Human Genome Sciences
( HGSI) for its hepatitis C drug Zalbin.
More FDA drug approval decisions coming next week:
on Monday night,
on Tuesday night.
, makes all-or-nothing bet on its lung drug pirfenidone.
As chief executive, David Nance drove
into bankruptcy and disgrace, but his best pal Texas Gov. Rick Perry continues to supply Nance with taxpayer funds.
The Dallas Morning News has all the illuminating details
The week's worst-performing sector stocks:
( BLUD) (-17.1%) and
Wait… I thought
was going to buy
? Rumor mill says Pfizer
The Wall Street Journal's
Ron Winslow writes about an innovative
@adamfeuerstein's tweet of the week:
$SOMX -- 4 weeks since the Silenor launch... Guess how many scripts have been written? C'mon, guess...
The answer is... 99 Silenor scripts! Not 99 dozen scripts.
in four weeks. Ouch. $SOMX making $VNDA's Fanapt look like a rocket.
Factoid: The number of publicly traded biotech companies in the U.S. has dropped by 25% in the past three years, according to the Biotechnology Industry Organization. Me: 25%? Is that all? Should be more.
pulled the weight-loss drug Meridia from U.S. market.
sits down with
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.